Early Access — free while we kick the tires
EdgarHawk

MOORE JOHN A

Chairman

Director Officer
9 filings analyzed · 1 company · Latest 2026-03-24

Companies

Company Buys Sells Direction
SCIENTIFIC INDUSTRIES INC SCND 9 0 Net buying

Activity

March 2026
medium
Buy
9,000 shares
$5,220
Significance 5/10

Chairman Moore buys 9,000 shares at $0.58 amid 46.3% decline from 52-week high

JOHN A MOORE, Chairman, purchased 9,000 shares at $0.58 on 2026-03-23, increasing his stake to 926,871 shares. The purchase occurs amid significant recent weakness: the stock is down 46.3% from its 52-week high of $1.08 and down 21.7% over the past 30 days. At this ticker specifically, Moore's prior 4 measurable trades show a 75% success rate on 90-day outcomes (3 of 4 well-timed), with two December 2025 buys returning +39.2% and +36.2% respectively, though his cross-ticker track record is more modest (33.33% win rate, -5.3% average 90d return). However, the fundamental backdrop is concerning: the company posted annual revenue decline of -3.6% and was unprofitable over its most recent full fiscal year, despite a small positive net income in the latest quarter. The timing of this buy during a steep drawdown warrants tracking against the company's trajectory, especially given ongoing profitability questions.

medium
Buy
1,000 shares
$650
Significance 4/10

Chairman Moore buys 1,000 shares at $0.65; stock up 27.3% in 30 days, but company faced FY net income decline.

John A Moore, Chairman, purchased 1,000 shares at $0.65 on 2026-02-19, increasing his holdings from 916,871 to 917,871 shares. The stock has appreciated 27.3% over the past 30 days and now trades at $0.74, up 31.6% over 90 days. However, his same-ticker history shows mixed outcomes: of 5 prior SCND purchases, only 3 posted positive 90-day returns, a 60% success rate, and the most recent prior buys in mid-December achieved notable gains (+11.0% and +8.6% at 30 days). The fundamental picture is complex—while the latest quarter showed $4.0M net income, the company was unprofitable over its most recent full fiscal year and revenue declined 3.6% year-over-year. The current market cap of $8.8M and minimal annual revenue ($1.4M quarterly) suggest a micro-cap with elevated execution risk.

December 2025
medium
Buy
11,700 shares
$6,359
Significance 4/10

SCND Chairman John A Moore bought 11,700 shares at $0.54 on 2025-12-17 amid -50.8% pullback from 52-week high; stock down 20.7% in 30 days.

John A Moore, Chairman of Scientific Industries Inc, purchased 11,700 shares at $0.54, expanding his holdings from 645.2K shares to 656.9K shares. The transaction occurred as the stock trades at $0.59, down -50.8% from its 52-week high of $1.20 and declining -20.7% over the past 30 days. At the same ticker, Moore's three prior measurable buys over the past several months (2025-09-17, 2025-09-16, 2025-04-18) all showed negative 90-day returns (-21.0%, -15.6%, and -42.0% respectively), with none qualifying as well-timed at the 90-day mark. The company generated $1.4M in quarterly revenue with reported net income of $4.0M, but was unprofitable over its most recent full fiscal year and faces declining annual revenue (-3.6% year-over-year). The recurring pattern of purchase timing misaligned with subsequent price performance at this ticker, combined with deteriorating fundamentals, presents a noteworthy data point for scrutiny.

medium
Buy
6,500 shares
$3,455
Significance 3/10

Chairman John A Moore buys 6,500 shares of SCND at $0.53; stock down 50.8% from 52-week high, now $0.59.

John A Moore, the Chairman of Scientific Industries Inc, purchased 6,500 shares at $0.53 on 2025-12-17, increasing his holdings to 663,371 shares. This is his second purchase in 12 days and part of a pattern of five consecutive buy transactions at this ticker since April 2025. However, his prior three measurable purchases at SCND have produced poor results: the 2025-04-18 buy yielded a 90-day return of -42.0%, while the 2025-09-16 and 2025-09-17 buys produced 90-day returns of -15.6% and -21.0% respectively, with 0 of 3 prior buys well-timed at the 90-day mark. The stock is currently trading at $0.59, down 50.8% from its 52-week high of $1.20 and down 20.7% over the past 30 days. The company's fundamentals are stressed: it reported annual revenue growth of -3.6%, was unprofitable over its most recent full fiscal year, and carries a market cap of $7.0M against quarterly revenue of only $1.4M. The repeated buying despite deteriorating stock performance and weak fundamentals may reflect efforts to support or stabilize the stock rather than conviction about value recovery.

low
Buy
20,000 shares
$12,096
Significance 3/10

Chairman JOHN A MOORE bought 20,000 shares ($0.60, $12.1K) as stock down -55.0% from 52-week high

JOHN A MOORE purchased 20,000 shares at $0.60 on 2025-12-05, increasing his holdings to 645.2K shares (+3.2%). The purchase occurs amid significant price weakness: the stock trades at $0.54, down -55.0% from its 52-week high and -23.9% over the prior 30 days. However, his prior trades at this ticker show mixed timing: only 1 of 4 measurable prior buys at SCND delivered positive 90-day returns, and his cross-ticker track record shows a 12.50% win rate over 90 days with an average 90-day return of -17.5%. Fundamentally, the company reported $1.4M quarterly revenue with full-year net income negative, though the latest quarter showed $4.0M net income; annual revenue declined -3.6% year-over-year. The purchase signal is ambiguous—it could reflect opportunistic accumulation at depressed prices, but his historical execution at this ticker and across holdings provides limited evidence of consistent market timing acumen.

September 2025
low
Buy
9,599 shares
$6,143
Significance 3/10

Director John A Moore bought 9,599 shares of Scientific Industries at $0.64, growing stake to 461.3K shares amid stock at 52-week low.

John A Moore, a director, purchased 9,599 shares at $0.64 on 2025-09-16, increasing his holdings from 451.7K to 461.3K shares. The transaction occurred at a stock price -45.3% from the 52-week high of $1.28, and the current price of $0.70 reflects modest recovery from the purchase level. At the same-ticker level, Moore's prior 4 measurable buys at Scientific Industries yielded only 1 well-timed outcome at the 90-day mark, with returns of -20.0%, -42.0%, +7.0%, -20.5%, and -25.3%. The company's fundamentals remain pressured: latest quarterly revenue of $2.3M, net income of $-1.5M, and full-year unprofitability compound the weakness. While the director's purchase adds to the stake, the company's operating losses, revenue contraction of -3.6% year-over-year, and his inconsistent timing record at this ticker limit the signal strength of this incremental buy.

medium
Buy
5,800 shares
$4,060
Significance 3/10

Chairman John A Moore buys 5,800 shares of Scientific Industries (scnd) at $0.70 on 2025-09-17, raising holdings to 467.1K shares despite -45.3% drop from 52-week high.

Moore purchased 5,800 shares at $0.70, the day after buying the same quantity at identical price, yet the stock trades 45.3% below its 52-week high of $1.28 and has declined 15.2% in the past 30 days. His same-ticker buy history shows 1 well-timed purchase out of 4 measurable outcomes at Scientific Industries, with three prior buys posting negative 90-day returns ranging from -20.5% to -42.0%. The company reported net income of $-1.5M on revenue of $2.3M last quarter and is unprofitable on a full-year basis, with annual revenue declining 3.6% year-over-year. The back-to-back purchases on consecutive days at an identical price, combined with weak recent price action and the company's unprofitable fundamentals, warrant scrutiny of whether these trades reflect independent conviction or follow a mechanical pattern.

May 2025
medium
Buy
35,000 shares
$35,000
Significance 4/10

SCND Chairman buys 35,000 shares at $1.00; stock down -64.0% from 52-week high, company unprofitable.

John A Moore, Chairman of Scientific Industries Inc, purchased 35,000 shares at $1.00 on 2025-04-18, increasing his holdings by 33.4% to 139,782 shares. The purchase occurs against a backdrop of significant price deterioration: the stock trades at $0.80, down -64.0% from its 52-week high of $2.22 and down -21.6% over the preceding 30 days. Fundamentals remain challenging, with the company reporting negative net income of $-1.8M on quarterly revenue of $2.4M and annual revenue decline of -3.6%. Moore's same-ticker history at SCND shows mixed outcomes: his 2024-10-31 buy delivered +30.8% in 30 days and +7.0% in 90 days, but his two June 2024 buys showed minimal and negative returns respectively. Only 1 of his 3 measurable prior SCND buys achieved positive 90-day returns, suggesting limited success timing purchases at this ticker. The timing and magnitude of this buy relative to recent sharp declines and persistent unprofitability warrant close monitoring of subsequent quarterly results.

October 2024
medium
Buy
7,000 shares
$6,755
Significance 3/10

Chairman Moore buys 7,000 SCND shares at $0.96; stock down 74.2% from 52-week high, company unprofitable.

Chairman John A Moore purchased 7,000 shares at $0.96 on 2024-10-31, a small addition (1.5% increase) to his existing 479.8K-share position in Scientific Industries, which has a market cap of $10.8M and is currently unprofitable with full-year net income of $-1.3M and annual revenue declining 2.5%. The timing is notable in context: the stock is -74.2% from its 52-week high and has fallen -19.8% over the past 30 days and -33.1% over 90 days. Examining Moore's prior trade history at this ticker, none of his 5 prior buys achieved positive 90-day returns—all declined substantially—suggesting a pattern of acquisitions during downturns that have failed to recover. While the chairman's sustained accumulation despite fundamental weakness (unprofitable operations, revenue contraction) and prior poor outcomes at this specific ticker warrants attention from value-focused investors, the modest share volume and significant valuation pressure signal a speculative situation rather than a confidence-driven repricing signal.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access